特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
962704

局所薬物送達の世界市場・COVID-19の影響 (~2025年):製品タイプ (半固体 (クリーム・軟膏・ゲル・ローション)・液体・固体・経皮製品)・経路 (皮膚・直腸・膣)・施設区分・地域別

Topical Drug Delivery Market by Type (Semisolids (Creams, Ointments, Gels, Lotions, Liquids, Solids, Transdermal Products), Route (Dermal, Rectal, Vaginal), Patient Care Setting COVID-19 Impact - Global Forecast to 2025

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 264 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
局所薬物送達の世界市場・COVID-19の影響 (~2025年):製品タイプ (半固体 (クリーム・軟膏・ゲル・ローション)・液体・固体・経皮製品)・経路 (皮膚・直腸・膣)・施設区分・地域別
出版日: 2020年09月29日
発行: MarketsandMarkets
ページ情報: 英文 264 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の局所薬物送達の市場規模は予測期間中6.4%のCAGRで推移し、2020年の952億米ドルから、2025年には1298億米ドルの規模に成長すると予測されています。皮膚および軟部組織感染症の高い有病率、眼疾患、火傷の増加などの要因が同市場の成長を推進しています。一方で、経口および注射などの経路による代替薬物送達モードの存在が市場のさらなる成長の妨げとなる見通しです。

製品別で見ると、半固体製剤の部門が期間中最大のCAGRを示す見通しです。半固形製剤の利用の容易さ、多様な薬物分子の送達能力などのメリットから安定した需要がもたらされています。また、投与経路別では、経皮部門が最大のCAGRを示すと予測されています。利便性や患者の服薬コンプライアンスの向上、規制要件の相対的な少なさなどの要因が同部門の成長を推進しています。

当レポートでは、世界の局所薬物送達の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、市場規模の推移・予測、製品・投与経路・施設区分・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 制限
    • 市場機会
    • 課題
  • COVID-19の影響

第6章 市場分析・予測:製品別

  • 半固体製剤
    • クリーム
    • 軟膏
    • ローション
    • ジェル
    • ペースト
  • 液体製剤
    • 懸濁液
    • 溶液
  • 固体製剤
    • パウダー
    • 坐剤
  • 経皮吸収剤
    • 経皮パッチ
    • 経皮半固形剤

第7章 市場分析・予測:投与経路別

  • 皮膚
  • 直腸
  • 経鼻

第8章 市場分析・予測:施設別

  • 在宅医療
  • 病院・クリニック
  • 火傷治療センター
  • その他

第9章 市場分析・予測:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • その他
  • その他の地域

第10章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合シナリオ
  • 競合リーダーシップマッピング

第11章 企業プロファイル

  • BAUSCH HEALTH COMPANIES
  • HISAMITSU PHARMACEUTICAL
  • NESTLE SA
  • GLENMARK PHARMACEUTICALS
  • CIPLA
  • CRESCITA THERAPEUTICS INC.
  • MYLAN N.V.
  • GLAXOSMITHKLINE
  • JANSSEN GLOBAL SERVICES
  • 3M
  • MERCK & CO.
  • BAYER AG
  • NOVARTIS AG
  • BOEHRINGER INGELHEIM
  • PFIZER, INC.
  • 他の主要企業
    • TEVA PHARMACEUTICALS
    • BRISTOL-MYERS SQUIBB
    • LEAD CHEMICALS CO., INC.
    • LAVIPHARM
    • PURDUE PHARMA L.P.

第12章 付録

目次
Product Code: PH 7545

Title:
Topical Drug Delivery Market
by Type (Semisolids (Creams, Ointments, Gels, Lotions, Liquids, Solids, Transdermal Products), Route (Dermal, Rectal, Vaginal), Patient Care Setting (Homecare, Hospital, Burn Center) COVID-19 Impact - Global Forecast to 2025.

The topical drug delivery market is projected to reach USD 129.8 billion by 2025 from USD 95.2 billion in 2020, at a CAGR of 6.4% during the forecast period. The growth of this market is majorly driven by the high prevalence of skin and soft tissue infections, the increasing prevalence of eye diseases, and burns. However, the presence of alternative drug delivery modes such as oral and injectable routes is expected to restrain the growth of this market during the forecast period.

Based on product, the semi-solid formulations segment holds the largest market share during the forecast period.

Based on product, the topical drug delivery market is segmented into semi-solid formulations, liquid formulations, solid formulations, and transdermal products. The semi-solid formulations segment accounted for the larger market share in 2019. The easy application of semi-solid formulations, and their ability to deliver a wide variety of drug molecules is resulting in a stable demand for this segment among end users.

Based on route of administration, the dermal drug delivery segment is expected to register the highest CAGR during the forecast period.

Based on route of administration, the topical drug delivery market is segmented into dermal drug delivery, ophthalmic drug delivery, rectal, vaginal drug delivery, and nasal drug delivery. The dermal drug delivery segment is expected to witness the highest growth during the forecast period. This is mainly due to the advantages of dermal drug delivery over other topical drug delivery methods, such as convenience and greater patient compliance. Besides, dermal products have fewer regulatory requirements than ophthalmic products, where sterility testing is mandatory.

The home care settings segment is expected to account for the largest share of the topical drug delivery market in 2019

The home care settings segment accounted for the largest share of the market in 2019. This is attributed to the factors such as the convenience and affordability of topical drugs for home administration. Also, for patients requiring long-term therapy, inpatient care is not only extremely expensive but also prevents patients from resuming a normal lifestyle and work activities. In this regard, technological advancements have helped patients undergo therapies effectively and safely at home.

Asia Pacific is expected to grow at the highest CAGR in the topical drug delivery market during the forecast period

The topical drug delivery market in the Asia Pacific is estimated to grow at the highest CAGR during the forecast period. This is due to high incidence of skin diseases (such as skin cancer), increasing use of contraceptives, and the growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, all of which are driving adoption of topical drug delivery in the Asia Pacific.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-55%, Tier 2-25% and Tier 3-20%
  • By Designation - C-level-43%, Director-level-32%, Others-25%
  • By Region - North America-38%, Europe-29%, Asia Pacific-23%, RoW- 10%

Key players in the topical drug delivery market

The key players operating in the topical drug delivery market include: Johnson & Johnson (US), Nestle SA (Switzerland), Novartis AG (Switzerland), GlaxoSmithKline (UK), Bausch Health Companies (Canada), Merck & Co (US), Bayer AG (Germany), Hisamitsu Pharmaceutical (Japan), Glenmark Pharmaceuticals (India), Cipla Ltd (India), Crescita Therapeutics Inc. (Canada), Mylan (US), Encore Dermatology, Inc. (US), LEO Pharma (Denmark), Almirall, S.A (Spain), Aclaris Therapeutics, Inc. (US), Taro Pharmaceutical Industries Ltd. (US), Teligent Pharma (US), Perrigo Pharma (US), Allergan (Ireland), Biofrontera, Inc. (US), Crown Laboratories Inc. (US), Akorn Inc. (US), Ingenus Pharmaceuticals (US), and Sun Pharmaceuticals (India).

Research Coverage:

The report analyzes the topical drug delivery market and aims at estimating the market size and future growth potential of this market based on various segments such as product, route of administration, facility of use, and region. The report also includes a product portfolio matrix of various topical drug delivery products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global topical drug delivery market. The report analyzes this market by product, route of administration, and facility of use
  • Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global topical drug delivery market
  • Market Development: Comprehensive information on the lucrative emerging markets by product, route of administration, and facility of use
  • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global topical drug delivery market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global topical drug delivery market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
    • 1.2.2 MARKETS COVERED
    • FIGURE 1 TOPICAL DRUG DELIVERY MARKET SEGMENTATION
    • 1.2.3 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 TOPICAL DRUG DELIVERY MARKET: RESEARCH METHODOLOGY
    • FIGURE 3 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
  • 2.2 MARKET SIZING & VALIDATION APPROACH
    • FIGURE 5 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
    • FIGURE 6 TOP-DOWN APPROACH
  • 2.3 MARKET DATA VALIDATION AND TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

    • FIGURE 8 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020 VS 2025 (USD MILLION)
    • FIGURE 9 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020 VS 2025 (USD MILLION)
    • FIGURE 10 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020 VS 2025 (USD MILLION)
    • FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE TOPICAL DRUG DELIVERY MARKET

4 PREMIUM INSIGHTS

  • 4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW
    • FIGURE 12 HIGH PREVALENCE OF SKIN DISEASES AND HIGH INCIDENCE OF BURN INJURIES TO DRIVE THE GROWTH OF THE TOPICAL DRUG DELIVERY MARKET
  • 4.2 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT AND COUNTRY, 2019
    • FIGURE 13 SEMI-SOLID FORMULATIONS TO DOMINATE THE ASIA PACIFIC MARKET DURING THE FORECAST PERIOD
  • 4.3 TOPICAL DRUG DELIVERY MARKET, BY REGION (2018-2025)
    • FIGURE 14 NORTH AMERICA WILL CONTINUE TO DOMINATE THE TOPICAL DRUG DELIVERY MARKET IN 2025
  • 4.4 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 15 CHINA TO SHOW THE HIGHEST REVENUE GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 16 TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 High prevalence of skin diseases
      • 5.2.1.2 Rising prevalence of eye diseases
      • 5.2.1.3 High incidence of burn injuries
      • 5.2.1.4 Growing prevalence of diabetes
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Preference for alternative modes of drug delivery
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Delivery of biologics through the transdermal route
      • 5.2.3.2 Self-administration and home care
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Technical barriers related to skin irritation and permeability
      • 5.2.4.2 Drug failures and product recalls
  • 5.3 COVID-19 IMPACT ON THE TOPICAL DRUG DELIVERY MARKET
    • FIGURE 17 IMPACT OF COVID-19 ON THE TOPICAL DRUG DELIVERY MARKET

6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 COVID-19 IMPACT, BY PRODUCT
    • FIGURE 18 SEMI-SOLID FORMULATIONS SEGMENT TO COMMAND THE LARGEST SHARE OF THE MARKET IN 2019
    • TABLE 1 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 2 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
  • 6.3 SEMI-SOLID FORMULATIONS
    • TABLE 3 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 4 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 5 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 6 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2020-2025 (USD MILLION)
    • 6.3.1 CREAMS
      • 6.3.1.1 Ease of spreadability and washability to drive this market segment
    • TABLE 7 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 8 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY, 2020-2025 (USD MILLION)
    • 6.3.2 OINTMENTS
      • 6.3.2.1 Ointments are widely used in analgesic indications
    • TABLE 9 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 10 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY, 2020-2025 (USD MILLION)
    • 6.3.3 LOTIONS
      • 6.3.3.1 Easy administration of lotions to drive their demand among end users
    • TABLE 11 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 12 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY, 2020-2025 (USD MILLION)
    • 6.3.4 GELS
      • 6.3.4.1 Faster drug release and greater patient acceptability to drive the market for topical gels
    • TABLE 13 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 14 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY, 2020-2025 (USD MILLION)
    • 6.3.5 PASTES
      • 6.3.5.1 Topical pastes are widely used for the treatment and prevention of skin irritation
    • TABLE 15 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 16 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY, 2020-2025 (USD MILLION)
  • 6.4 LIQUID FORMULATIONS
    • TABLE 17 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 18 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 19 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 20 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2020-2025 (USD MILLION)
    • 6.4.1 SUSPENSIONS
      • 6.4.1.1 Higher rate of bioavailability and controlled onset of action to support the growth of the topical suspensions market
    • TABLE 21 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 22 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY, 2020-2025 (USD MILLION)
    • 6.4.2 SOLUTIONS
      • 6.4.2.1 Topical solutions comprise soluble chemicals that are dissolved in various solvents
    • TABLE 23 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 24 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY, 2020-2025 (USD MILLION)
  • 6.5 SOLID FORMULATIONS
    • TABLE 25 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 26 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 27 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 28 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2020-2025 (USD MILLION)
    • 6.5.1 POWDERS
      • 6.5.1.1 Powders have a very fine particle size that covers a large surface area per unit weight
    • TABLE 29 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 30 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY, 2020-2025 (USD MILLION)
    • 6.5.2 SUPPOSITORIES
      • 6.5.2.1 Suppositories require a suitable base that ensures the compatibility and stability of the drug
    • TABLE 31 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 32 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES, BY COUNTRY, 2020-2025 (USD MILLION)
  • 6.6 TRANSDERMAL PRODUCTS
    • TABLE 33 COMPARISON BETWEEN TRANSDERMAL PATCHES AND TRANSDERMAL SEMI-SOLID FORMULATIONS
    • TABLE 34 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 35 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 36 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 37 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2020-2025 (USD MILLION)
    • 6.6.1 TRANSDERMAL PATCHES
      • 6.6.1.1 Transdermal patches accounted for the largest share of the transdermal drug delivery market in 2019
    • TABLE 38 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 39 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY COUNTRY, 2020-2025 (USD MILLION)
    • 6.6.2 TRANSDERMAL SEMI-SOLIDS
      • 6.6.2.1 Transdermal semi-solids segment to witness negative growth during the forecast period
    • TABLE 40 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL SEMI-SOLIDS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 41 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL SEMI-SOLIDS, BY COUNTRY, 2020-2025 (USD MILLION)

7 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION

  • 7.1 INTRODUCTION
  • 7.2 COVID-19 IMPACT, BY ROUTE OF ADMINISTRATION
    • FIGURE 19 DERMAL DRUG DELIVERY TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
    • TABLE 42 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 43 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
  • 7.3 DERMAL DRUG DELIVERY
    • 7.3.1 DERMAL DRUG DELIVERY IS THE LARGEST SEGMENT IN THIS MARKET
    • TABLE 44 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 45 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
  • 7.4 OPHTHALMIC DRUG DELIVERY
    • 7.4.1 INCREASING USE OF MOBILE DEVICES IS LIKELY TO IMPACT VISION, WHICH IS A KEY FACTOR SUPPORTING MARKET GROWTH
    • TABLE 46 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 47 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
  • 7.5 RECTAL DRUG DELIVERY
    • 7.5.1 POOR ABSORPTION OF DRUGS THROUGH THE RECTAL ROUTE-A KEY DISADVANTAGE ASSOCIATED WITH THIS MARKET SEGMENT
    • TABLE 48 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 49 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
  • 7.6 VAGINAL DRUG DELIVERY
    • 7.6.1 SCOPE OF SELF-ADMINISTRATION AND EASE OF MANUFACTURING TO BOOST THE GROWTH OF THE VAGINAL DRUG DELIVERY MARKET SEGMENT
    • TABLE 50 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 51 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
  • 7.7 NASAL DRUG DELIVERY
    • 7.7.1 HIGH EFFICACY OF NASALLY ADMINISTERED DRUGS AND GROWING PREFERENCE FOR SELF-ADMINISTRATION TO DRIVE MARKET GROWTH
    • TABLE 52 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 53 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2020-2025 (USD MILLION)

8 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE

  • 8.1 INTRODUCTION
    • FIGURE 20 HOME CARE SETTINGS SEGMENT TO COMMAND THE LARGEST SHARE OF THE MARKET IN 2019
    • TABLE 54 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 55 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION)
  • 8.2 HOME CARE SETTINGS
    • 8.2.1 HOME CARE SETTINGS ACCOUNTED FOR THE LARGEST SHARE IN 2019
    • TABLE 56 TOPICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 57 TOPICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2020-2025 (USD MILLION)
  • 8.3 HOSPITALS AND CLINICS
    • 8.3.1 RISING INCIDENCE OF SURGICAL-SITE INFECTIONS TO DRIVE MARKET GROWTH
    • TABLE 58 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 59 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020-2025 (USD MILLION)
  • 8.4 BURN CENTERS
    • 8.4.1 HIGH INCIDENCE OF BURN INJURIES ACROSS THE GLOBE TO SUPPORT THE MARKET GROWTH
    • TABLE 60 TOPICAL DRUG DELIVERY MARKET FOR BURN CENTERS, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 61 TOPICAL DRUG DELIVERY MARKET FOR BURN CENTERS, BY COUNTRY, 2020-2025 (USD MILLION)
  • 8.5 OTHER FACILITIES
    • TABLE 62 TOPICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 63 TOPICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES, BY COUNTRY, 2020-2025 (USD MILLION)

9 TOPICAL DRUG DELIVERY MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 COVID-19 IMPACT, BY REGION
    • FIGURE 21 CHINA TO WITNESS THE HIGHEST GROWTH IN THE TOPICAL DRUG DELIVERY MARKET
    • TABLE 64 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2019 (USD MILLION)
    • TABLE 65 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2020-2025 (USD MILLION)
  • 9.3 NORTH AMERICA
    • FIGURE 22 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
    • TABLE 66 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 67 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
    • TABLE 68 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 69 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
    • TABLE 70 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 71 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 72 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 73 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 74 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 75 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 76 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 77 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 78 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 79 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
    • TABLE 80 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 81 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION)
    • 9.3.1 US
      • 9.3.1.1 Rising prevalence of skin diseases and the approval and launch of innovative topical formulations-key factors driving market growth
    • TABLE 82 PRODUCT APPROVALS & LAUNCHES IN THE US MARKET (2017-2019)
    • TABLE 83 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 84 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
    • TABLE 85 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 86 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 87 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 88 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 89 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 90 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 91 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 92 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 93 US: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 94 US: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
    • TABLE 95 US: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 96 US: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION)
    • 9.3.2 CANADA
      • 9.3.2.1 Rising prevalence of skin diseases and funding for the development of topical drugs to drive market growth
    • TABLE 97 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 98 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
    • TABLE 99 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 100 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 101 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 102 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 103 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 104 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 105 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 106 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 107 CANADA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 108 CANADA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
    • TABLE 109 CANADA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 110 CANADA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION)
  • 9.4 EUROPE
    • TABLE 111 RECENT DEVELOPMENTS IN THE EUROPEAN TOPICAL DRUG DELIVERY MARKET, 2015-2018
    • FIGURE 23 EUROPE: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
    • TABLE 112 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 113 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
    • TABLE 114 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 115 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
    • TABLE 116 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 117 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 118 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 119 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 120 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 121 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 122 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 123 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 124 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 125 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
    • TABLE 126 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 127 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION)
    • 9.4.1 GERMANY
      • 9.4.1.1 Growing focus of pharmaceutical companies on the development of topical products to drive market growth
    • TABLE 128 DEVELOPMENTS IN THE FIELD OF TOPICAL DRUG DELIVERY IN GERMANY, 2017-2019
    • TABLE 129 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 130 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
    • TABLE 131 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 132 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 133 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 134 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 135 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 136 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 137 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 138 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 139 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 140 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
    • TABLE 141 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 142 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION) 154
    • 9.4.2 UK
      • 9.4.2.1 Rising prevalence of skin diseases & chronic conditions to drive market growth
    • TABLE 143 DEVELOPMENTS IN THE TOPICAL DRUG DELIVERY MARKET IN THE UK, 2016-2019
    • TABLE 144 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 145 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
    • TABLE 146 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 147 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 148 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 149 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 150 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 151 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 152 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 153 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 154 UK: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 155 UK: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
    • TABLE 156 UK: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 157 UK: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION)
    • 9.4.3 FRANCE
      • 9.4.3.1 Rising prevalence of skin diseases and development of topical drugs by local players to support market growth
    • TABLE 158 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 159 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
    • TABLE 160 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 161 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 162 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 163 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 164 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 165 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 166 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 167 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 168 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 169 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
    • TABLE 170 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 171 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION)
    • 9.4.4 REST OF EUROPE
    • TABLE 172 ROE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 173 ROE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
    • TABLE 174 ROE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 175 ROE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 176 ROE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 177 ROE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 178 ROE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 179 ROE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 180 ROE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 181 ROE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 182 ROE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 183 ROE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
    • TABLE 184 ROE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 185 ROE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION)
  • 9.5 ASIA PACIFIC
    • TABLE 186 DEVELOPMENTS IN THE TOPICAL DRUG DELIVERY MARKET IN THE ASIA PACIFIC, 2016-2019
    • FIGURE 24 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
    • TABLE 187 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 188 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
    • TABLE 189 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 190 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
    • TABLE 191 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 192 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 193 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 194 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 195 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 196 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 197 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 198 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 199 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 200 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
    • TABLE 201 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 202 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION)
    • 9.5.1 JAPAN
      • 9.5.1.1 Increasing number of product approvals and growing focus of local players on the R&D of topical formulations to support market growth
    • TABLE 203 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 204 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
    • TABLE 205 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 206 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 207 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 208 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 209 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 210 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 211 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 212 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 213 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 214 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
    • TABLE 215 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 216 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION)
    • 9.5.2 CHINA
      • 9.5.2.1 Growing focus of major players in China on the development of topical drugs to drive market growth
    • TABLE 217 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 218 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
    • TABLE 219 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 220 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 221 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 222 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 223 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 224 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 225 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 226 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 227 CHINA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 228 CHINA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
    • TABLE 229 CHINA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 230 CHINA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION)
    • 9.5.3 INDIA
      • 9.5.3.1 Rising awareness among healthcare providers & patients and increasing focus on noninvasive methods of drug delivery to drive market growth
    • TABLE 231 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 232 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
    • TABLE 233 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 234 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 235 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 236 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 237 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 238 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 239 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 240 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 241 INDIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 242 INDIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
    • TABLE 243 INDIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 244 INDIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION)
    • 9.5.4 REST OF ASIA PACIFIC
    • TABLE 245 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 246 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
    • TABLE 247 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 248 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 249 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 250 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 251 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 252 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 253 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 254 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 255 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 256 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
    • TABLE 257 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 258 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION)
  • 9.6 REST OF THE WORLD
    • FIGURE 25 REST OF THE WORLD: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
    • TABLE 259 ROW: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2019 (USD MILLION)
    • TABLE 260 ROW: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020-2025 (USD MILLION)
    • TABLE 261 ROW: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 262 ROW: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 263 ROW: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 264 ROW: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 265 ROW: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 266 ROW: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 267 ROW: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 268 ROW: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 269 ROW: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2019 (USD MILLION)
    • TABLE 270 ROW: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2025 (USD MILLION)
    • TABLE 271 ROW: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017-2019 (USD MILLION)
    • TABLE 272 ROW: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020-2025 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 MARKET SHARE ANALYSIS
    • FIGURE 26 MARKET SHARE ANALYSIS BY KEY PLAYERS (2019)
  • 10.3 COMPETITIVE SCENARIO
    • 10.3.1 PRODUCT LAUNCHES
    • TABLE 273 PRODUCT LAUNCHES
    • 10.3.2 EXPANSIONS
    • TABLE 274 EXPANSIONS
    • 10.3.3 AGREEMENTS AND COLLABORATIONS
    • TABLE 275 AGREEMENTS AND COLLABORATIONS
    • 10.3.4 ACQUISITIONS
    • TABLE 276 ACQUISITIONS
  • 10.4 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET) (2019)
    • 10.4.1 STAR PLAYERS
    • 10.4.2 EMERGING LEADERS
    • 10.4.3 PERVASIVES
    • 10.4.4 EMERGING COMPANIES
    • FIGURE 27 TOPICAL DRUG DELIVERY MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2019

11 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, and MnM View)**

  • 11.1 BAUSCH HEALTH COMPANIES
    • FIGURE 28 BAUSCH HEALTH COMPANIES: COMPANY SNAPSHOT (2019)
  • 11.2 HISAMITSU PHARMACEUTICAL
    • FIGURE 29 HISAMITSU PHARMACEUTICAL: COMPANY SNAPSHOT (2019)
  • 11.3 NESTLE SA
    • FIGURE 30 NESTLE SA: COMPANY SNAPSHOT (2019)
  • 11.4 GLENMARK PHARMACEUTICALS
    • FIGURE 31 GLENMARK PHARMACEUTICALS: COMPANY SNAPSHOT (2019)
  • 11.5 CIPLA
    • FIGURE 32 CIPLA: COMPANY SNAPSHOT (2020)
  • 11.6 CRESCITA THERAPEUTICS INC.
    • FIGURE 33 CRESCITA THERAPEUTICS: COMPANY SNAPSHOT (2019)
  • 11.7 MYLAN N.V.
    • FIGURE 34 MYLAN: COMPANY SNAPSHOT (2019)
  • 11.8 GLAXOSMITHKLINE
    • FIGURE 35 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)
  • 11.9 JANSSEN GLOBAL SERVICES (A SUBSIDIARY OF JOHNSON & JOHNSON)
    • FIGURE 36 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019)
  • 11.10 3M
    • FIGURE 37 3M: COMPANY SNAPSHOT (2019)
  • 11.11 MERCK & CO.
    • FIGURE 38 MERCK & CO.: COMPANY SNAPSHOT (2019)
  • 11.12 BAYER AG
    • FIGURE 39 BAYER AG: COMPANY SNAPSHOT (2019)
  • 11.13 NOVARTIS AG
    • FIGURE 40 NOVARTIS AG: COMPANY SNAPSHOT (2019)
  • 11.14 BOEHRINGER INGELHEIM
    • FIGURE 41 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2019)
  • 11.15 PFIZER, INC.
    • FIGURE 42 PFIZER, INC.: COMPANY SNAPSHOT (2019)
  • 11.16 OTHER MAJOR COMPANIES
    • 11.16.1 TEVA PHARMACEUTICALS
    • 11.16.2 BRISTOL-MYERS SQUIBB
    • 11.16.3 LEAD CHEMICALS CO., INC.
    • 11.16.4 LAVIPHARM
    • 11.16.5 PURDUE PHARMA L.P.

*Details on Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 RELATED REPORTS
  • 12.4 AUTHOR DETAILS 275
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.